Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

This study has been terminated.
(The results of the dose escalation phase did not identify a well-tolerated dose that would permit further study in Phase 2.)
Information provided by (Responsible Party):
Kyowa Kirin Pharmaceutical Development, Inc. ( Kyowa Hakko Kirin Pharma, Inc. ) Identifier:
First received: September 8, 2010
Last updated: April 4, 2014
Last verified: April 2014

This study will determine the highest dose of KW-2450 in combination with lapatinib and letrozole that can be administered safely to subjects with advanced or metastatic breast cancer and to evaluate its effectiveness.

This study was terminated in Phase 1 and never proceeded to the Phase 2 portion of the study.

Condition Intervention Phase
Breast Cancer
Drug: KW-2450 in combination with lapatinib and letrozole
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KW-2450 in Combination With Lapatinib and Letrozole in Subjects With Advanced or Metastatic Breast Cancer Whose Tumors Overexpress HER2

Resource links provided by NLM:

Further study details as provided by Kyowa Kirin Pharmaceutical Development, Inc.:

Primary Outcome Measures:
  • To establish the safety, tolerability, and recommended Phase 2 dose of KW-2450 administered in combination with lapatinib and letrozole in subjects with previously treated or untreated advanced breast cancer. [ Time Frame: 30 Days ]

Secondary Outcome Measures:
  • To determine the PK profile of KW-2450, lapatinib, and letrozole when administered together [ Time Frame: 1 year (or until PD) ]

Enrollment: 11
Study Start Date: December 2010
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dose escallation Drug: KW-2450 in combination with lapatinib and letrozole
Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
Other Name: KW-2450 lapatinib and letrozole

Detailed Description:

This open-label, sequential, ascending, multi-dose, Phase 1/2 study will enroll up to 198 post-menopausal subjects with advanced or metastatic breast cancer whose tumors overexpress HER2. Subjects at each dose level will receive KW-2450 orally, on a continuous daily schedule in combination with lapatinib and letrozole.

In the Phase 1 portion of the study, dose escalation may proceed once ≥ 3 subjects have completed Day 30. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially. Up to 6 subjects may be enrolled at each dose level. Enrollment will proceed until the MTD has been established or the highest dose level has been reached.

The Phase 2 portion of the trial will enroll 168 additional subjects. The dose level will be based on overall safety and tolerability assessments from the Phase 1 portion of the study. The subjects will be randomized into two treatment arms (1) Arm A, KW-2450 plus lapatinib plus letrozole: (2) Arm B, lapatinib plus letrozole.

This study was terminated in Phase 1 and never proceeded to the Phase 2 portion of the study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Histopathologically or cytologically confirmed, advanced or metastatic breast cancer (stage IIIb, IIIc or IV disease) including inflammatory breast cancer or inoperable locally advanced disease.
  2. Documented ErbB2 overexpression
  3. Estrogen receptor positive (ER+) and/or progesterone positive (PgR+) tumors
  4. Measurable or non-measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria
  5. A life expectancy of > 3 months for Phase 1 and > 6 months for Phase 2
  6. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2 at study entry in Phase 1 and ≤ 1 in Phase 2;
  7. Normal cardiac ejection fraction
  8. Adequate hematologic, hepatic and renal function
  9. Post-menopausal female (defined as the absence of a menstrual cycle for at least 12 consecutive months) or male subjects ≥ 18 years of age.
  10. Sign an IRB or EC approved informed consent

Exclusion Criteria

  1. Type 1 diabetes or uncontrolled Type 2 diabetes
  2. Subjects showing clinical evidence or with a history of cataract(s), proliferate retinopathy or significant macular edema
  3. Subjects with abnormal free T4 values and a history or evidence of thyroid disease
  4. Subjects who are unable or unwilling to take metformin
  5. Uncontrolled intercurrent illness
  6. Known or suspected human immunodeficiency virus (HIV) infection or hepatitis B or C
  7. Subjects with inflammatory diseases of the gastrointestinal tract
  8. History of other malignancy. Subjects who have been disease free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;
  9. Subjects with extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor
  10. A history of prior treatment with other agents specifically targeting IGFRs
  11. Subjects who require pharmacological doses of glucocorticoids beyond replacement doses. The use of topical, intra-ocular or inhalation glucocorticoids is permitted
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01199367

United States, California
Breastlink Research Group
Long Beach, California, United States, 90250
Associates in Hematology-Oncology
Los Angeles, California, United States, 90057
United States, Florida
Sylvester Comprehensive Cancer Center
Deerfield Beach, Florida, United States, 33136
United States, Michigan
Clinical Oncology Associates
Farmington Hills, Michigan, United States, 48336
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Kyowa Hakko Kirin Pharma, Inc.
Study Director: Michael Kurman, MD Kyowa Hakko Kirin Pharma, Inc.
  More Information

Dickson MA, P. LoRusso P, E. A. Sausville EA, Rao N, Kobayashi E, Kurman MR, Akinaga S, Schwartz GK. Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors. J Clin Oncol 29: 2011 (suppl; abstr 3078)

Responsible Party: Kyowa Hakko Kirin Pharma, Inc. Identifier: NCT01199367     History of Changes
Other Study ID Numbers: 2450-US-002
Study First Received: September 8, 2010
Last Updated: April 4, 2014

Keywords provided by Kyowa Kirin Pharmaceutical Development, Inc.:
advanced or metastatic breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 25, 2017